UCLA Professor of Neurosurgery and NeuroSigma Co-Founder Honored for Groundbreaking Work including Deep Brain Stimulation for Treatment of PTSD
LOS ANGELES, March 21, 2012 /PRNewswire/ — NeuroSigma, Inc., a Los Angeles-based medical device company, is pleased to recognize the accomplishments of Antonio A.F. De Salles, M.D., Ph.D., Professor of Neurosurgery and Head of the Stereotactic Surgery Division of the Department of Neurosurgery at UCLA, as one of the 2012 recipients of the Pioneer in Medicine Award from the Society of Brain Mapping and Therapeutics (SBMT). The Society is honoring Dr. De Salles with the award in recognition of his significant contribution to frameless stereotactic radiosurgery and his groundbreaking work in the use of Deep Brain Stimulation (DBS) for the potential treatment of Post-Traumatic Stress Disorder (PTSD).
“I am humbled by this award and would like to take this opportunity to thank the Society and to acknowledge all the members of my research team at UCLA, the VA and NeuroSigma, in particular Drs. Alessandra Gorgulho, JP Langevin and Scott Krahl,” noted Dr. De Salles.
The Society will officially honor Dr. De Salles and other award recipients at the Brain Mapping Foundation’s Gala on June 1, 2012 as part of their 9(th) Annual World Congress in Toronto, Canada.
“Dr. De Salles is truly a pioneer in the field of neuroscience and we are delighted to see his dedication and important work in DBS being recognized through this prestigious award,” said Lodwrick Cook, Chairman of NeuroSigma. “With an estimated 7.7 million American adults affected by PTSD, including many veterans, it is encouraging to see the development of this promising treatment option and we are honored to have Dr. De Salles as a key member of our team.”
As a co-founder of NeuroSigma and a Senior Medical Advisor to the company, Dr. De Salles is spearheading NeuroSigma’s implantable neuromodulation development activities, including DBS for the potential treatment of obesity and PTSD; and subcutaneous trigeminal nerve stimulation (sTNS(TM)) for the potential treatment of epilepsy, depression and PTSD.
CAUTION: DBS for the treatment of PTSD and obesity and the sTNS(TM) system are investigational devices and at this time are limited by United States law for investigational use only.
About NeuroSigma, Inc.
NeuroSigma is a Los Angeles-based medical technology company established to develop early stage technologies with the potential to transform medical practice. Currently, NeuroSigma is focused on a number of neuromodulation therapies and through our majority-owned subsidiary, NSVascular, on Thin-Film Nitinol covered stents for endovascular applications. NeuroSigma employs two neuromodulation therapy platforms: Trigeminal Nerve Stimulation (TNS) and Deep Brain Stimulation (DBS). NeuroSigma has amassed significant intellectual property that is based on technology licensed on an exclusive basis from the University of California, Los Angeles (UCLA), including potential therapies for epilepsy, depression and post-traumatic stress disorder (PTSD) via TNS and for PTSD, obesity and cachexia via DBS. For more information about NeuroSigma, please visit our website at http://www.neurosigma.com.
SOURCE NeuroSigma, Inc.